Because of the dearth of FDA –approved medications for eating disorders, psychotherapy has gradually become the treatment of choice. Nonetheless, clinical trials of off-label uses of various medications have yielded a few impressive results, particularly for bulimia and binge eating disorder.
Read More
A variety of psychotherapy techniques work well for eating disorders, particularly for bulimia nervosa and binge eating disorder. This article gives a brief summary of the evidence from controlled clinical trials.
Read More
A recent follow-up of the Multisite Treatment Study of Children with ADHD (MTA) study investigated the long-term course of ADHD and the impact of short-term treatment on long-term outcomes.
Read More
Researchers assessed predictors of suicidal events and non-suicidal self-harm in a group of 334 moderately to severely depressed adolescents (ages 12-18) who had not responded to at least eight weeks of SSRI treatment.
Read More
In a 2005 public health advisory, the FDA warned that antipsychotics appear to increase the rate of mortality in elderly patients with dementia. The implication is that we should discontinue such agents in this population when possible. But does this actually decrease the mortality risk?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
